Sun Chuan, Ni Mingming, Song Bo, Cao Lu
Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
Front Pharmacol. 2020 Nov 13;11:560537. doi: 10.3389/fphar.2020.560537. eCollection 2020.
Heart failure (HF) is a serious, chronic disease, causing significant ill health and high mortality worldwide. The current clinical strategies emphasize reducing the transition from a healthy to a failing heart despite the shift in the clinical goal from healing to disease prevention. Recent research advancements on noncoding RNAs (ncRNAs) have demonstrated that circular RNAs (circRNAs) are significant therapeutic targets in HF. Previous studies have highlighted the potential applicability of circRNAs in the diagnosis and treatment of diseases. However, less is known regarding the potential benefits of circRNAs as novel diagnostic and treatment biomarkers for HF. In the present study, we summarize the current developments and achievements associated with the use of circRNAs as HF biomarkers. We also discuss future research directions regarding HF diagnosis and treatment.
心力衰竭（HF）是一种严重的慢性疾病，在全球范围内导致严重的健康问题和高死亡率。尽管临床目标已从治愈转向疾病预防，但目前的临床策略仍强调减少从健康心脏向衰竭心脏的转变。非编码RNA（ncRNAs）的最新研究进展表明，环状RNA（circRNAs）是HF的重要治疗靶点。先前的研究强调了circRNAs在疾病诊断和治疗中的潜在适用性。然而，关于circRNAs作为HF新型诊断和治疗生物标志物的潜在益处，人们了解较少。在本研究中，我们总结了与使用circRNAs作为HF生物标志物相关的当前进展和成果。我们还讨论了HF诊断和治疗的未来研究方向。
